- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02630537
Validation of Lophius Kits T-Track® CMV and T-Track® EBV in Hemodialysis Patients
Clinical Validation of Lophius Kits T-Track® CMV and T-Track® EBV to Assess the Functionality of Cell-mediated Immunity (CMI) in Hemodialysis Patients
Cell-mediated immunity (CMI) and in particular T cells play a critical role in the rejection of transplanted organs. Thus, in transplant recipients a life-long and individualized immunosuppressive medication is required to avoid graft rejection. However, a too weak suppression of CMI causes acute and chronic graft damage leading to transplant loss, whereas a too potent suppression of CMI supports opportunistic infections and reactivation of persistent viruses.
One of the biggest challenges in the field of transplantation is to provide a personalized immunosuppressive and antiviral therapy based on reliable assessment and monitoring of CMI. This could lead to a reduction of graft rejections and virus reactivations in transplant recipients.
With the development of both assays T-Track® CMV and T-Track® EBV, Lophius Biosciences GmbH has implemented its novel proprietary T-activation technology for an improved assessment of the functionality of CMI in cytomegalovirus (CMV)- and/or Epstein-Barr virus (EBV)-seropositive individuals. In contrast to other existing systems the Lophius assays open up the opportunity to characterize the functionality of CMI as an entire network.
The planned clinical multicenter study aims to verify the suitability of the two assays for a reliable assessment of the functionality of CMI.
Hemodialysis patients have been identified as an appropriate patient cohort for investigating the clinical sensitivity of the Lophius assays as these patients closely resemble kidney transplant recipients prior to an immunosuppressive therapy.
The determination of the functional CMI in the course of an immunosuppressive treatment may in future enable physicians to optimize the individual immunosuppressive and antiviral therapy in transplant recipients to reduce the risk of rejection as well as virus reactivations and associated diseases.
Study Overview
Status
Conditions
Study Type
Enrollment (Actual)
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Patient being hemodialysis-dependent due to end-stage kidney disease
- Male or female patient at least 18 years of age
- Written informed consent
Exclusion Criteria:
- Patient requires ongoing dosing with a systemic immunosuppressive drug
- Patient has received immunosuppressive therapy within the last three month
- Patient is known to be positive for HIV or suffering from chronic hepatitis infections
- Patient has significant uncontrolled concomitant infections or other unstable medical conditions that could interfere with the study objectives
- Patient has any form of substance abuse, psychiatric disorder or condition that, in the opinion of the investigator may invalidate communication with the investigator
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of CMV or EBV seropositive hemodialysis patients showing significant numbers of functional CMV or EBV-protein-reactive blood leucocytes applying T-Track® CMV or T-Track® EBV
Time Frame: 1 day
|
Determination of the clinical sensitivity of T-Track® CMV and T-Track® EBV.
T-Track® assays are based on the stimulation of peripheral blood mononuclear cells (PBMC) with preselected immunodominant T-activated proteins derived from the human Cytomegalovirus (CMV) and the Epstein-Barr-Virus (EBV) and the subsequent quantification of IFN-gamma producing blood leucocytes (Lophius biomarker for assessing the functionality of CMI) applying ELISpot technology.
|
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of CMV or EBV seropositive hemodialysis patients showing significant numbers of functional CMV or EBV-protein-reactive blood leucocytes applying EBV and CMV peptide-loaded Pro5® Pentamers and the Quantiferon® CMV assay
Time Frame: 1 day
|
The comparison of the suitability of T-Track® CMV and T-Track® EBV to EBV and CMV peptide-loaded Pro5® Pentamers and the Quantiferon® CMV assay (commercially available competing products)
|
1 day
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Bernhard Banas, Prof., University Medical Center Regensburg
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- LB-A1 (UREA-CMV-EBV)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Renal Failure Chronic Requiring Dialysis
-
Ottawa Hospital Research InstituteUniversity of Manitoba; St. Joseph's Healthcare Hamilton; University Health Network... and other collaboratorsTerminated
-
Nantes University HospitalCompletedRenal Failure Chronic Requiring DialysisFrance
-
NxStage MedicalCompletedKidney Failure, Chronic | End Stage Renal Disease, Requiring DialysisUnited States
-
Lund UniversityBaxter Healthcare Corporation; Universidad de CórdobaCompletedEnd Stage Kidney Disease | Chronic Kidney Disease Requiring Chronic DialysisArgentina
-
University Hospital Birmingham NHS Foundation TrustCompletedPeritoneal Dialysis | Chronic Renal Failure | End Stage Renal Failure | Continuous Ambulatory Peritoneal DialysisUnited Kingdom
-
Peripal AGUniversity Hospital Birmingham NHS Foundation Trust; Swiss Federal Institute...CompletedRenal Failure | Peritoneal Dialysis | Renal Replacement Therapy | End Stage Renal Failure on Dialysis | End Stage Renal Disease on DialysisUnited Kingdom
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Puerto Rico
-
Rockwell Medical Technologies, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States, Canada
-
Baxter Healthcare CorporationGambro Dialysatoren GmbHCompletedRenal Failure Chronic Requiring HemodialysisAustria
-
Baxter Healthcare CorporationUniversity of Louisville; Gambro Renal Products, Inc.CompletedRenal Failure Chronic Requiring HemodialysisUnited States